Market Overview:
On the basis of application, it is classified into hospitals, clinics, and others. Geographically speaking, it covers North America,, Latin America,, Europe,, Asia Pacific,, Middle East & Africa,. Some key players operating in this market are Alnylam Pharmaceuticals Inc., Akcea Therapeutics Inc., Ionis Pharmaceuticals Inc., Sanofi S.A., Pfizer Inc., Regeneron Pharmaceuticals Inc.
Product Definition:
It is used to lower high levels of triglycerides and cholesterol in the blood.
Alipogene Tiparvovec:
Alipogene tiparvovec is an investigational drug developed by the pharmaceutical company named after Novartis and Pfizer.
CAT-2003:
CAT-2003 works by increasing high cholesterol levels in patients which are linked with increased risk for cardiovascular diseases, thus helping to reduce this disease's progression.
Application Insights:
The hospital segment dominated the overall market in terms of revenue in 2017 owing to a large patient base with lipid disorders across various regions.
Regional Analysis:
The presence of key players, favorable reimbursement scenario, and increasing prevalence of diabetes are some factors responsible for its large share. In addition, introduction of novel drugs such as alipogene tiparvovec and CAT-2003 is expected to further fuel the regional growth over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to rising disposable income leading to improved healthcare access & infrastructure development coupled with growing awareness about various treatment options among patients & physicians. Moreover, availability of generic version for many branded drugs due their patent expirations or because they no longer meet a therapeutic need will drive this market during the forecast period (2018 - 2030).
Growth Factors:
- Increasing prevalence of type I hyperlipoproteinemia
- Growing awareness about the disease and its treatment options
- Rising demand for novel and more effective therapies for type I hyperlipoproteinemia
- Availability of government funding for research on type I hyperlipoproteinemia drugs
- Technological advancements in the field of drug development
Scope Of The Report
Report Attributes
Report Details
Report Title
Type I Hyperlipoproteinemia Drug Market Research Report
By Type
Alipogene Tiparvovec, CAT-2003, ISIS-APOCIIIRx, Lomitapide Mesylate, Pradigastat Sodium, Others
By Application
Hospital, Clinic, Others
By Companies
Aegerion Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Novartis AG, uniQure N.V.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
154
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Type I Hyperlipoproteinemia Drug Market Report Segments:
The global Type I Hyperlipoproteinemia Drug market is segmented on the basis of:
Types
Alipogene Tiparvovec, CAT-2003, ISIS-APOCIIIRx, Lomitapide Mesylate, Pradigastat Sodium, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aegerion Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals, Inc.
- Isis Pharmaceuticals, Inc.
- Novartis AG
- uniQure N.V.
Highlights of The Type I Hyperlipoproteinemia Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alipogene Tiparvovec
- CAT-2003
- ISIS-APOCIIIRx
- Lomitapide Mesylate
- Pradigastat Sodium
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Type I Hyperlipoproteinemia Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Type I hyperlipoproteinemia is a rare genetic disorder that causes abnormally high levels of lipids in the blood. These lipids can include cholesterol, triglycerides, and fatty acids. People with type I hyperlipoproteinemia often have difficulty controlling their blood pressure and cholesterol levels, and may experience other health problems due to their high lipid levels. Treatment for type I hyperlipoproteinemia typically includes lifestyle changes such as diet and exercise, medications to lower lipid levels, or both.
Some of the major players in the type i hyperlipoproteinemia drug market are Aegerion Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Novartis AG, uniQure N.V..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Type I Hyperlipoproteinemia Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Type I Hyperlipoproteinemia Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Type I Hyperlipoproteinemia Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Type I Hyperlipoproteinemia Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Type I Hyperlipoproteinemia Drug Market Size & Forecast, 2018-2028 4.5.1 Type I Hyperlipoproteinemia Drug Market Size and Y-o-Y Growth 4.5.2 Type I Hyperlipoproteinemia Drug Market Absolute $ Opportunity
Chapter 5 Global Type I Hyperlipoproteinemia Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Type I Hyperlipoproteinemia Drug Market Size Forecast by Type
5.2.1 Alipogene Tiparvovec
5.2.2 CAT-2003
5.2.3 ISIS-APOCIIIRx
5.2.4 Lomitapide Mesylate
5.2.5 Pradigastat Sodium
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Type I Hyperlipoproteinemia Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Type I Hyperlipoproteinemia Drug Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Type I Hyperlipoproteinemia Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Type I Hyperlipoproteinemia Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Type I Hyperlipoproteinemia Drug Analysis and Forecast
9.1 Introduction
9.2 North America Type I Hyperlipoproteinemia Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Type I Hyperlipoproteinemia Drug Market Size Forecast by Type
9.6.1 Alipogene Tiparvovec
9.6.2 CAT-2003
9.6.3 ISIS-APOCIIIRx
9.6.4 Lomitapide Mesylate
9.6.5 Pradigastat Sodium
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Type I Hyperlipoproteinemia Drug Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Type I Hyperlipoproteinemia Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Type I Hyperlipoproteinemia Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Type I Hyperlipoproteinemia Drug Market Size Forecast by Type
10.6.1 Alipogene Tiparvovec
10.6.2 CAT-2003
10.6.3 ISIS-APOCIIIRx
10.6.4 Lomitapide Mesylate
10.6.5 Pradigastat Sodium
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Type I Hyperlipoproteinemia Drug Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Type I Hyperlipoproteinemia Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Type I Hyperlipoproteinemia Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Type I Hyperlipoproteinemia Drug Market Size Forecast by Type
11.6.1 Alipogene Tiparvovec
11.6.2 CAT-2003
11.6.3 ISIS-APOCIIIRx
11.6.4 Lomitapide Mesylate
11.6.5 Pradigastat Sodium
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Type I Hyperlipoproteinemia Drug Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Type I Hyperlipoproteinemia Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Type I Hyperlipoproteinemia Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Type I Hyperlipoproteinemia Drug Market Size Forecast by Type
12.6.1 Alipogene Tiparvovec
12.6.2 CAT-2003
12.6.3 ISIS-APOCIIIRx
12.6.4 Lomitapide Mesylate
12.6.5 Pradigastat Sodium
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Type I Hyperlipoproteinemia Drug Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Type I Hyperlipoproteinemia Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Type I Hyperlipoproteinemia Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Type I Hyperlipoproteinemia Drug Market Size Forecast by Type
13.6.1 Alipogene Tiparvovec
13.6.2 CAT-2003
13.6.3 ISIS-APOCIIIRx
13.6.4 Lomitapide Mesylate
13.6.5 Pradigastat Sodium
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Type I Hyperlipoproteinemia Drug Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Type I Hyperlipoproteinemia Drug Market: Competitive Dashboard
14.2 Global Type I Hyperlipoproteinemia Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aegerion Pharmaceuticals, Inc.
14.3.2 Catabasis Pharmaceuticals, Inc.
14.3.3 Isis Pharmaceuticals, Inc.
14.3.4 Novartis AG
14.3.5 uniQure N.V.